Published in Diabetologia on February 04, 2006
Atorvastatin Versus Vitamin E in Treatment of Non-alcoholic Fatty Liver Disease | NCT01720719
Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans. J Clin Invest (2009) 7.09
Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. Proc Natl Acad Sci U S A (2009) 5.64
Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology (2010) 5.35
Gender differences in insulin resistance, body composition, and energy balance. Gend Med (2009) 3.19
Liver, muscle, and adipose tissue insulin action is directly related to intrahepatic triglyceride content in obese subjects. Gastroenterology (2008) 3.04
Inhibition of apolipoprotein B100 secretion by lipid-induced hepatic endoplasmic reticulum stress in rodents. J Clin Invest (2008) 2.58
Postreceptor insulin resistance contributes to human dyslipidemia and hepatic steatosis. J Clin Invest (2009) 2.53
Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease. Gastroenterology (2007) 2.29
Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease. J Gastroenterol (2010) 2.06
Arsenic and cardiovascular disease. Toxicol Sci (2008) 1.90
Mechanisms linking nonalcoholic fatty liver disease with coronary artery disease. Dig Dis Sci (2011) 1.74
Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. Nutrients (2013) 1.73
Body fat distribution and inflammation among obese older adults with and without metabolic syndrome. Obesity (Silver Spring) (2010) 1.71
Sex differences in lipid and lipoprotein metabolism: it's not just about sex hormones. J Clin Endocrinol Metab (2011) 1.55
Increased very low density lipoprotein (VLDL) secretion, hepatic steatosis, and insulin resistance. Trends Endocrinol Metab (2011) 1.53
Triglycerides as vascular risk factors: new epidemiologic insights. Curr Opin Cardiol (2009) 1.45
Thyroid hormone-related regulation of gene expression in human fatty liver. J Clin Endocrinol Metab (2009) 1.44
Fructose consumption: recent results and their potential implications. Ann N Y Acad Sci (2010) 1.40
Hepatic stearoyl-CoA desaturase (SCD)-1 activity and diacylglycerol but not ceramide concentrations are increased in the nonalcoholic human fatty liver. Diabetes (2008) 1.24
Ethnic differences in lipoprotein subclasses in obese adolescents: importance of liver and intraabdominal fat accretion. Am J Clin Nutr (2010) 1.23
Reproducibility of glucose, fatty acid and VLDL kinetics and multi-organ insulin sensitivity in obese subjects with non-alcoholic fatty liver disease. Int J Obes (Lond) (2010) 1.18
Randomized trial of exercise effect on intrahepatic triglyceride content and lipid kinetics in nonalcoholic fatty liver disease. Hepatology (2012) 1.18
Nutritional systems biology modeling: from molecular mechanisms to physiology. PLoS Comput Biol (2009) 1.18
Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis. PLoS Med (2014) 1.14
Increased whole-body adiposity without a concomitant increase in liver fat is not associated with augmented metabolic dysfunction. Obesity (Silver Spring) (2010) 1.14
Peroxisome proliferator activated receptors and lipoprotein metabolism. PPAR Res (2008) 1.12
FoxO1 integrates insulin signaling to VLDL production. Cell Cycle (2008) 1.12
New insights into the mechanism of low high-density lipoprotein cholesterol in obesity. Lipids Health Dis (2011) 1.10
Banting Memorial lecture 2012: reversing the twin cycles of type 2 diabetes. Diabet Med (2013) 1.09
Type 2 diabetes: etiology and reversibility. Diabetes Care (2013) 1.06
Assessment of the variations in fat content in normal liver using a fast MR imaging method in comparison with results obtained by spectroscopic imaging. Eur Radiol (2007) 1.04
A subset of dysregulated metabolic and survival genes is associated with severity of hepatic steatosis in obese Zucker rats. J Lipid Res (2009) 1.01
Sugar consumption, metabolic disease and obesity: The state of the controversy. Crit Rev Clin Lab Sci (2015) 1.00
Severity of nonalcoholic fatty liver disease and progression to cirrhosis are associated with atherogenic lipoprotein profile. Clin Gastroenterol Hepatol (2014) 1.00
E4orf1 improves lipid and glucose metabolism in hepatocytes: a template to improve steatosis & hyperglycemia. PLoS One (2012) 0.99
Naringenin prevents cholesterol-induced systemic inflammation, metabolic dysregulation, and atherosclerosis in Ldlr⁻/⁻ mice. J Lipid Res (2012) 0.98
A dose-response study of consuming high-fructose corn syrup-sweetened beverages on lipid/lipoprotein risk factors for cardiovascular disease in young adults. Am J Clin Nutr (2015) 0.97
Lipid-lowering agents in nonalcoholic fatty liver disease and steatohepatitis: human studies. Dig Dis Sci (2012) 0.96
Pathophysiology of diabetic dyslipidaemia: where are we? Diabetologia (2015) 0.96
Prediction of non-alcoholic fatty-liver disease and liver fat content by serum molecular lipids. Diabetologia (2013) 0.95
Hepatic ABCA1 and VLDL triglyceride production. Biochim Biophys Acta (2011) 0.95
Lipoprotein subfractions in metabolic syndrome and obesity: clinical significance and therapeutic approaches. Nutrients (2013) 0.94
Fenofibrate increases very low density lipoprotein triglyceride production despite reducing plasma triglyceride levels in APOE*3-Leiden.CETP mice. J Biol Chem (2010) 0.94
Prandial hypertriglyceridemia in metabolic syndrome is due to an overproduction of both chylomicron and VLDL triacylglycerol. Diabetes (2013) 0.92
Improved cholesterol phenotype analysis by a model relating lipoprotein life cycle processes to particle size. J Lipid Res (2009) 0.92
Hepatic Steatosis as a Marker of Metabolic Dysfunction. Nutrients (2015) 0.92
The challenges for molecular nutrition research 2: quantification of the nutritional phenotype. Genes Nutr (2008) 0.92
A Mediterranean-style low-glycemic-load diet increases plasma carotenoids and decreases LDL oxidation in women with metabolic syndrome. J Nutr Biochem (2011) 0.91
Long-lasting improvements in liver fat and metabolism despite body weight regain after dietary weight loss. Diabetes Care (2013) 0.91
Lipoprotein metabolism in nonalcoholic fatty liver disease. J Biomed Res (2012) 0.90
Do obese but metabolically normal women differ in intra-abdominal fat and physical activity levels from those with the expected metabolic abnormalities? A cross-sectional study. BMC Public Health (2010) 0.89
Transplantation or removal of intra-abdominal adipose tissue prevents age-induced glucose insensitivity. Physiol Behav (2010) 0.89
The association of alanine aminotransferase within the normal and mildly elevated range with lipoproteins and apolipoproteins: the Insulin Resistance Atherosclerosis Study. Diabetologia (2013) 0.89
Impaired fasting glucose and impaired glucose tolerance have distinct lipoprotein and apolipoprotein changes: the insulin resistance atherosclerosis study. J Clin Endocrinol Metab (2013) 0.89
Lipoprotein subclass metabolism in nonalcoholic steatohepatitis. J Lipid Res (2014) 0.88
The Subtle Balance between Lipolysis and Lipogenesis: A Critical Point in Metabolic Homeostasis. Nutrients (2015) 0.87
Dietary carnosic acid suppresses hepatic steatosis formation via regulation of hepatic fatty acid metabolism in high-fat diet-fed mice. Nutr Res Pract (2013) 0.87
Greater dietary fat oxidation in obese compared with lean men: an adaptive mechanism to prevent liver fat accumulation? Am J Physiol Endocrinol Metab (2010) 0.87
A differential network approach to exploring differences between biological states: an application to prediabetes. PLoS One (2011) 0.87
Associations of visceral and liver fat with the metabolic syndrome across the spectrum of obesity: the AGES-Reykjavik study. Obesity (Silver Spring) (2010) 0.87
Hepatic senescence marker protein-30 is involved in the progression of nonalcoholic fatty liver disease. J Gastroenterol (2009) 0.86
An Endocrine Perspective of Nonalcoholic Fatty Liver Disease (NAFLD). Ther Adv Endocrinol Metab (2011) 0.86
The regulation of ApoB metabolism by insulin. Trends Endocrinol Metab (2013) 0.85
Plant stanol esters lower serum triacylglycerol concentrations via a reduced hepatic VLDL-1 production. Lipids (2009) 0.85
Apolipoprotein E4 exaggerates diabetic dyslipidemia and atherosclerosis in mice lacking the LDL receptor. Diabetes (2011) 0.84
Lipolysis, and not hepatic lipogenesis, is the primary modulator of triglyceride levels in streptozotocin-induced diabetic mice. Arterioscler Thromb Vasc Biol (2014) 0.84
Apolipoprotein B secretion is regulated by hepatic triglyceride, and not insulin, in a model of increased hepatic insulin signaling. Arterioscler Thromb Vasc Biol (2011) 0.84
Portal vein and systemic adiponectin concentrations are closely linked with hepatic glucose and lipoprotein kinetics in extremely obese subjects. Metabolism (2011) 0.84
Hepatic fatty acid trafficking: multiple forks in the road. Adv Nutr (2013) 0.82
The crude extract from puerariae flower exerts antiobesity and antifatty liver effects in high-fat diet-induced obese mice. Evid Based Complement Alternat Med (2012) 0.82
Genome metabolome integrated network analysis to uncover connections between genetic variants and complex traits: an application to obesity. J R Soc Interface (2014) 0.81
Low-normal thyroid function and novel cardiometabolic biomarkers. Nutrients (2015) 0.81
Fatty acid and very low density lipoprotein metabolism in obese African American and Caucasian women with type 2 diabetes. J Lipid Res (2012) 0.81
Serum TG-lowering properties of plant sterols and stanols are associated with decreased hepatic VLDL secretion. J Lipid Res (2014) 0.81
The severity of Fatty liver disease relating to metabolic abnormalities independently predicts coronary calcification. Radiol Res Pract (2011) 0.81
Incretin based therapies: a novel treatment approach for non-alcoholic fatty liver disease. World J Gastroenterol (2014) 0.81
The genetics of familial combined hyperlipidaemia. Nat Rev Endocrinol (2012) 0.81
Insulin glargine in the management of diabetes mellitus: an evidence-based assessment of its clinical efficacy and economic value. Core Evid (2007) 0.80
The impact of education on weight loss in overweight and obese adults. Int Cardiovasc Res J (2013) 0.80
In vivo postprandial lipid partitioning in liver and skeletal muscle in prediabetic and diabetic rats. Diabetologia (2012) 0.80
Mathematical modelling of competitive LDL/VLDL binding and uptake by hepatocytes. J Math Biol (2008) 0.79
Interrelationship Between Periapical Lesion and Systemic Metabolic Disorders. Curr Pharm Des (2016) 0.79
Complex effects of inhibiting hepatic apolipoprotein B100 synthesis in humans. Sci Transl Med (2016) 0.79
Effects of 4 weeks recombinant human growth hormone administration on insulin resistance of skeletal muscle in rats. Yonsei Med J (2008) 0.79
Fatty liver in men is associated with high serum levels of small, dense low-density lipoprotein cholesterol. Diabetol Metab Syndr (2012) 0.79
Omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid and their mechanisms of action on apolipoprotein B-containing lipoproteins in humans: a review. Lipids Health Dis (2017) 0.79
Nuclear receptors in nonalcoholic Fatty liver disease. J Lipids (2011) 0.78
World Congress on Insulin Resistance, Diabetes, and Cardiovascular Disease: part 3. Diabetes Care (2011) 0.78
Menopausal Status and Abdominal Obesity Are Significant Determinants of Hepatic Lipid Metabolism in Women. J Am Heart Assoc (2015) 0.78
Metabolic characterization of the natural progression of chronic hepatitis B. Genome Med (2016) 0.78
Utility of hypertriglyceridemic waist phenotype for predicting incident type 2 diabetes: The Isfahan Diabetes Prevention Study. J Diabetes Investig (2016) 0.78
Personal model-assisted identification of NAD(+) and glutathione metabolism as intervention target in NAFLD. Mol Syst Biol (2017) 0.78
Inhibition of the central melanocortin system decreases brown adipose tissue activity. J Lipid Res (2014) 0.77
Atherogenic dyslipidemia and combination pharmacotherapy in diabetes: recent clinical trials. Rev Diabet Stud (2013) 0.77
Hepatoprotective Effect of Houttuynia cordata Thunb Extract against Carbon Tetrachloride-induced Hepatic Damage in Mice. Indian J Pharm Sci (2014) 0.77
Olea europaea Linn. Fruit Pulp Extract Protects against Carbon Tetrachloride-induced Hepatic Damage in Mice. Indian J Pharm Sci (2014) 0.76
Kinetic Studies to Elucidate Impaired Metabolism of Triglyceride-rich Lipoproteins in Humans. Front Physiol (2015) 0.76
Minor Contribution of Endogenous GLP-1 and GLP-2 to Postprandial Lipemia in Obese Men. PLoS One (2016) 0.76
Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet (2007) 6.82
Use of the oral glucose tolerance test to assess insulin release and insulin sensitivity. Diabetes Care (2000) 4.14
Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med (2000) 3.90
The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases. Eur J Epidemiol (2007) 3.81
Impaired glucose tolerance as a disorder of insulin action. Longitudinal and cross-sectional studies in Pima Indians. N Engl J Med (1988) 3.41
A common variant in PNPLA3, which encodes adiponutrin, is associated with liver fat content in humans. Diabetologia (2009) 3.33
Skeletal muscle capillary density and fiber type are possible determinants of in vivo insulin resistance in man. J Clin Invest (1987) 2.96
Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes. Diabetes Obes Metab (2010) 2.30
Women and men have similar amounts of liver and intra-abdominal fat, despite more subcutaneous fat in women: implications for sex differences in markers of cardiovascular risk. Diabetologia (2004) 2.12
Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes. Diabetologia (2006) 1.89
Kinetics of glucose disposal in whole body and across the forearm in man. J Clin Invest (1987) 1.83
Natural course of insulin resistance in type I diabetes. N Engl J Med (1986) 1.82
Hyperuricemia and insulin resistance. J Clin Endocrinol Metab (1994) 1.82
Reproducibility of imaging human knee cartilage by delayed gadolinium-enhanced MRI of cartilage (dGEMRIC) at 1.5 Tesla. Osteoarthritis Cartilage (2008) 1.79
Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481]. Cardiovasc Diabetol (2005) 1.71
Hyperglycemia decreases glucose uptake in type I diabetes. Diabetes (1987) 1.58
Causes of weight gain during insulin therapy with and without metformin in patients with Type II diabetes mellitus. Diabetologia (1999) 1.58
Intramyocellular lipid is associated with resistance to in vivo insulin actions on glucose uptake, antilipolysis, and early insulin signaling pathways in human skeletal muscle. Diabetes (2001) 1.57
Serum saturated fatty acids containing triacylglycerols are better markers of insulin resistance than total serum triacylglycerol concentrations. Diabetologia (2009) 1.53
Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project. Circulation (2000) 1.51
Exercise in waist-high warm water decreases pain and improves health-related quality of life and strength in the lower extremities in women with fibromyalgia. Arthritis Rheum (2006) 1.51
Defective regulation of triglyceride metabolism by insulin in the liver in NIDDM. Diabetologia (1997) 1.49
Changes in muscle morphology, electromyographic activity, and force production characteristics during progressive strength training in young and older men. J Gerontol A Biol Sci Med Sci (1998) 1.48
Insulin increases the release of endothelin in endothelial cell cultures in vitro but not in vivo. Metabolism (1994) 1.42
Hyperreactivity to nitrovasodilators in forearm vasculature is related to autonomic dysfunction in insulin-dependent diabetes mellitus. Circulation (1997) 1.41
Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) subfractions: relative contribution of small, dense LDL to coronary heart disease risk. Atherosclerosis (1994) 1.40
Independent influence of age on basal insulin secretion in nondiabetic humans. European Group for the Study of Insulin Resistance. J Clin Endocrinol Metab (1999) 1.37
Physical training and insulin sensitivity. Diabetes Metab Rev (1986) 1.37
Activation of the hexosamine pathway by glucosamine in vivo induces insulin resistance of early postreceptor insulin signaling events in skeletal muscle. Diabetes (1999) 1.37
Acute suppression of VLDL1 secretion rate by insulin is associated with hepatic fat content and insulin resistance. Diabetologia (2007) 1.34
Familial combined hyperlipidaemia linked to the apolipoprotein AI-CII-AIV gene cluster on chromosome 11q23-q24. Nature (1991) 1.32
Tissue specificity of insulin resistance in humans: fat in the liver rather than muscle is associated with features of the metabolic syndrome. Diabetologia (2007) 1.31
Gender and insulin sensitivity in the heart and in skeletal muscles. Studies using positron emission tomography. Diabetes (1995) 1.30
Insulin resistance, hyperinsulinemia, and blood pressure: role of age and obesity. European Group for the Study of Insulin Resistance (EGIR). Hypertension (1997) 1.30
Circulating adiponectin levels are reduced in nonobese but insulin-resistant first-degree relatives of type 2 diabetic patients. Diabetes (2003) 1.28
Chronic hyperglycemia impairs endothelial function and insulin sensitivity via different mechanisms in insulin-dependent diabetes mellitus. Circulation (1996) 1.26
Regulation of glycogen synthase and phosphorylase activities by glucose and insulin in human skeletal muscle. J Clin Invest (1987) 1.25
Apolipoprotein B metabolism and the distribution of VLDL and LDL subfractions. J Lipid Res (2000) 1.25
Methodological aspects, dose-response characteristics and causes of interindividual variation in insulin stimulation of limb blood flow in normal subjects. Diabetologia (1995) 1.25
Biosynthesis of apolipoprotein B48-containing lipoproteins. Regulation by novel post-transcriptional mechanisms. J Biol Chem (1996) 1.24
Independent mutations at codon 3500 of the apolipoprotein B gene are associated with hyperlipidemia. Arterioscler Thromb Vasc Biol (1995) 1.22
Ectopic lipid storage and insulin resistance: a harmful relationship. J Intern Med (2013) 1.22
The assembly and secretion of apolipoprotein B-containing lipoproteins. Curr Opin Lipidol (1999) 1.22
Insulin regulates the serum levels of low molecular weight insulin-like growth factor-binding protein. J Clin Endocrinol Metab (1988) 1.22
A family history of diabetes is associated with reduced physical fitness in the Prevalence, Prediction and Prevention of Diabetes (PPP)-Botnia study. Diabetologia (2010) 1.22
Pulse-chase studies of the synthesis and intracellular transport of apolipoprotein B-100 in Hep G2 cells. J Biol Chem (1986) 1.19
Socioeconomic status and telomere length: the West of Scotland Coronary Prevention Study. J Epidemiol Community Health (2009) 1.19
Metabolic basis of hypotriglyceridemic effects of insulin in normal men. Arterioscler Thromb Vasc Biol (1997) 1.17
Insulin increases plasma leptin concentrations in normal subjects and patients with NIDDM. Diabetologia (1996) 1.16
Intense physical training decreases circulating antioxidants and endothelium-dependent vasodilatation in vivo. Atherosclerosis (1999) 1.16
Neuromuscular adaptations during concurrent strength and endurance training versus strength training. Eur J Appl Physiol (2002) 1.16
Genes for apolipoprotein B and microsomal triglyceride transfer protein are expressed in the heart: evidence that the heart has the capacity to synthesize and secrete lipoproteins. Circulation (1998) 1.14
Sex and insulin sensitivity. Metabolism (1984) 1.13
Transgenic mice that overexpress mouse apolipoprotein B. Evidence that the DNA sequences controlling intestinal expression of the apolipoprotein B gene are distant from the structural gene. J Biol Chem (1996) 1.12
Effects of insulin and acipimox on VLDL1 and VLDL2 apolipoprotein B production in normal subjects. Diabetes (1998) 1.11
Supraphysiological hyperinsulinemia increases plasma leptin concentrations after 4 h in normal subjects. Diabetes (1996) 1.11
Inhibition of the microsomal triglyceride transfer protein blocks the first step of apolipoprotein B lipoprotein assembly but not the addition of bulk core lipids in the second step. J Biol Chem (1996) 1.11
Insulin therapy induces antiatherogenic changes of serum lipoproteins in noninsulin-dependent diabetes. Arteriosclerosis (1988) 1.11
Impact of age and comorbidities on the criteria for remission and response in rheumatoid arthritis. Ann Rheum Dis (2005) 1.10
Selective muscle hypertrophy, changes in EMG and force, and serum hormones during strength training in older women. J Appl Physiol (1985) (2001) 1.10
Differential effects of oral and transdermal estrogen replacement therapy on endothelial function in postmenopausal women. Circulation (2000) 1.10
Collaborative meta-analysis of individual participant data from observational studies of Lp-PLA2 and cardiovascular diseases. Eur J Cardiovasc Prev Rehabil (2007) 1.10
Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and/or pioglitazone: a randomised double-blind placebo-controlled study. Diabetologia (2012) 1.09
In vivo endothelial dysfunction characterizes patients with impaired fasting glucose. Diabetes Care (1999) 1.09
Assembly of very low density lipoprotein: a two-step process of apolipoprotein B core lipidation. J Nutr (1999) 1.09
Studies on the assembly of apo B-100-containing lipoproteins in HepG2 cells. J Biol Chem (1988) 1.07
Relationship between lipid profiles and kidney function in patients with type 1 diabetes. Diabetologia (2007) 1.07
Role of blood flow in regulating insulin-stimulated glucose uptake in humans. Studies using bradykinin, [15O]water, and [18F]fluoro-deoxy-glucose and positron emission tomography. J Clin Invest (1996) 1.07
Purification of diacylglycerol:acyltransferase from rat liver to near homogeneity. J Lipid Res (1994) 1.07
Free fatty acid kinetics and oxidation in congestive heart failure. Am J Cardiol (1998) 1.07
Energy replacement attenuates the effects of prior moderate exercise on postprandial metabolism in overweight/obese men. Int J Obes (Lond) (2007) 1.06
Expression of fatty-acid-handling proteins in human adipose tissue in relation to obesity and insulin resistance. Diabetologia (2004) 1.06
Low-grade inflammation, endothelial activation and carotid intima-media thickness in type 2 diabetes. J Intern Med (2004) 1.06
Continuous subcutaneous insulin infusion therapy decreases insulin resistance in type 1 diabetes. J Clin Endocrinol Metab (1984) 1.05
Level of skeletal muscle glucose transporter protein correlates with insulin-stimulated whole body glucose disposal in man. Diabetologia (1991) 1.05
Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women. Thromb Haemost (2001) 1.05
TCF7L2 is associated with high serum triacylglycerol and differentially expressed in adipose tissue in families with familial combined hyperlipidaemia. Diabetologia (2007) 1.04
Atherogenic lipoprotein phenotype in end-stage renal failure: origin and extent of small dense low-density lipoprotein formation. Am J Kidney Dis (2000) 1.03
A male-specific quantitative trait locus on 1p21 controlling human stature. J Med Genet (2005) 1.03
15-Lipoxygenase-2 is expressed in macrophages in human carotid plaques and regulated by hypoxia-inducible factor-1alpha. Eur J Clin Invest (2009) 1.03
Fetal cord plasma lipoprotein status in uncomplicated human pregnancies and in pregnancies complicated by pre-eclampsia and intrauterine growth restriction. Atherosclerosis (2004) 1.02